NRG Oncology Network Group Operations Center

NRG 肿瘤网络集团运营中心

• 批准号: 10731902
• 负责人: Quynh-Thu Xuan Le
• 金额: $ 109.42万
• 依托单位: NRG ONCOLOGY FOUNDATION, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-03-01 至 2023-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10731902
• 关键词: Adult; African ancestry; Area; Awareness; Brain Neoplasms; Breast; Cancer Patient; Cancer Therapy Evaluation Program; Clinical Research; Clinical Trials; Collaborations; Development; Disease; Enrollment; Ensure; Gender; Goals; Gynecologic; Head and Neck Cancer; Hispanic; International; Latino; Lead; Leadership; Locally Advanced Malignant Neoplasm; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of lung; Malignant neoplasm of prostate; Malignant neoplasm of urinary bladder; Manuscripts; National Clinical Trials Network; Non-Hematologic Malignancy; Oncology; Patients; Peer Review; Positioning Attribute; Precision medicine trial; Protocols documentation; Publishing; Research; Scientific Advances and Accomplishments; Site; Translational Research; advanced disease; advanced prostate cancer; clinically relevant; cohort; design; improved; interest; malignant breast neoplasm; member; multidisciplinary; operation; participant enrollment; patient population; sarcoma; trial enrollment

NRG Overall Component Abstract NRG Oncology (NRG) has made significant progress toward its goal of improving the lives of adults with certain non-hematologic malignancies through its clinical and translational research efforts. NRG's defined patient populations of interest - those with gender-specific malignancies and/or those with localized or locally advanced disease, are unique within the NCTN, constituting a large and relatively under-investigated cohort of cancer patients. Positioned to be the lead NCTN research organization for trials enrolling several patient cohorts, NRG's portfolio focuses on patients with gynecologic cancer, primary or secondary brain tumors, head and neck cancer, or localized or locally advanced prostate cancer as well as breast cancer, lung cancer, gastrointestinal cancer, bladder cancer, or sarcoma. In these and other realms NRG, actively collaborates with other NCTN groups, diligently working to increase awareness of and participation in all NCTN trials. NRG's research accomplishments to date have been extraordinary. There have been 87 CTEP- supported NRG trials open for enrollment during this period, representing 34% of the open NCTN adult trials. For the period March 1, 2014 through August 31, 2017, NRG members entered 10,840 patients onto NRG-led trials, 3,199 patients into trials led by other NCTN network groups, and an additional 1,906 patients onto NCTN Precision Medicine Trials for a total of 15,945 entries. Of the 48,056 total NCTN treatment enrollments, NRG's contribution accounts for 33% of the total entries and represents the largest accrual of any of the five NCTN groups. Of patients enrolled onto NRG trials at U.S. sites, 12.7% were self-identified as of African descent and 8.0% as Latino or Hispanic. There have been 302 NRG peer-reviewed manuscripts published or in press and 365 published abstracts during this period, of which at least 52 contain practice-changing or practice-defining observations. To successfully fulfill its ambitious goal, NRG has seven cancer disease site committees, all with internationally recognized multi-disciplinary leadership and all with strong liaison representatives from NRG's nine scientific core committees. There are four other protocol-generating committees and five administrative committees, all designed to lead and support critical areas of the group's research. NRG is organized such that the necessary operational efficiencies and internal peer review are in order to overcome barriers to conducting a broad portfolio of scientifically important and relevant clinical trials and to ensuring appropriate enrollment to these trials.

NRG总体组件摘要 NRG肿瘤学(NRG)在改善人们生活的目标方面取得了重大进展 成人某些非血液系统恶性肿瘤的临床和翻译研究 努力。NRG确定的感兴趣的患者群体--那些患有特定性别的恶性肿瘤的人 和/或患有局部或局部晚期疾病的患者在NCTN中是独一无二的， 构成了一大群相对未被充分调查的癌症患者。定位为 NCTN试验的主要研究组织招募了几个患者队列，NRG的投资组合 主要针对妇科癌症、原发或继发性脑肿瘤、头颈部肿瘤患者 癌症，或局部或局部晚期前列腺癌，以及乳腺癌，肺癌， 胃肠癌、膀胱癌或肉瘤。在这些和其他领域，NRG积极 与其他NCTN小组合作，勤奋工作，提高对 参加所有NCTN试验。 到目前为止，NRG的研究成就是非同寻常的。已经有87个CTEP- 支持的NRG试验在此期间开放注册，占开放试验的34% NCTN成人试验。2014年3月1日至2017年8月31日期间，NRG成员 10,840名患者参加NRG领导的试验，3,199名患者参加其他NCTN领导的试验 网络小组，以及另外1,906名患者参加NCTN精密医学试验 共有15,945个条目。在48,056名NCTN治疗注册总人数中，NRG的贡献 占总条目的33%，是五个NCTN中最大的应计项目 组。在美国网站登记参加NRG试验的患者中，12.7%的患者自认为 非洲裔占8.0%，拉丁裔或西班牙裔占8.0%。 已经出版或出版的NRG同行评审稿有302篇，出版了365篇 这一时期的摘要，其中至少52篇包含实践改变或实践定义 观察。为了成功实现其雄心勃勃的目标，NRG拥有七个癌症疾病网站 委员会，都有国际公认的多学科领导，都有强大的 NRG的九个科学核心委员会的联络代表。还有另外四个 礼宾生成委员会和五个行政委员会，都旨在领导和 支持该小组研究的关键领域。NRG的组织方式是为了使必要的 业务效率和内部同行审查是为了克服开展 广泛的具有科学重要性和相关性的临床试验组合，并确保适当的 登记参加这些试验。